Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11

Benzinga Newsdesk www.benzinga.com Positive 52.2%

Neg 0% Neu 0% Pos 52.2%

Guggenheim analyst Vamil Divan initiates coverage on Entera Bio (NASDAQ:ENTX) with a Buy rating and announces Price Target of $11.